HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?

被引:39
作者
Chang, CC [1 ]
Campoli, M [1 ]
Ferrone, S [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA
关键词
D O I
10.1016/j.coi.2004.07.015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HLA class I antigen defects are frequently found in malignant cells. They appear to play a role in the clinical course of the disease, probably because they provide tumor cells with a mechanism to escape cytotoxic T lymphocyte (CTL) recognition and destruction. Expression of HLA class I antigens, however, is not always associated with the susceptibility of tumor cells to CTL lysis. Many mechanisms may underlie this finding, including the lack of tumor antigen (TA)-derived peptide presentation by a given HLA class I allospecificity, and/or the expression of immunosuppressive molecules such as HLA-G. These findings emphasize the need to develop probes to measure HLA class I allospecificity-TA peptide complex expression in malignant cells. Furthermore, the evaluation of the role of HLA class I antigens in the interaction of malignant cells with host immune cells should take into account the potential interference of tumor-derived immunomodulators.
引用
收藏
页码:644 / 650
页数:7
相关论文
共 64 条
[1]   Downregulation of Muc1 in MMTV-c-Neu tumors [J].
Adriance, MC ;
Gendler, SJ .
ONCOGENE, 2004, 23 (03) :697-705
[2]   TGF-β signaling in cancer -: a double-edged sword [J].
Akhurst, RJ ;
Derynck, R .
TRENDS IN CELL BIOLOGY, 2001, 11 (11) :S44-S51
[3]   ENDOGENOUSLY SYNTHESIZED PEPTIDE WITH AN ENDOPLASMIC-RETICULUM SIGNAL SEQUENCE SENSITIZES ANTIGEN PROCESSING MUTANT-CELLS TO CLASS-I-RESTRICTED CELL-MEDIATED LYSIS [J].
ANDERSON, K ;
CRESSWELL, P ;
GAMMON, M ;
HERMES, J ;
WILLIAMSON, A ;
ZWEERINK, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (02) :489-492
[4]  
[Anonymous], 2002, Diagnostic immunohistochemistry
[5]   Mhc class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma [J].
Atkins, D ;
Breuckmann, A ;
Schmahl, GE ;
Binner, P ;
Ferrone, S ;
Krummenauer, F ;
Strökel, S ;
Seliger, B .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (02) :265-273
[6]  
Bukur J, 2003, CANCER RES, V63, P4107
[7]  
Campoli M, 2004, CURR CLIN ONCOL, P3
[8]   HLA-G molecules: from maternal-fetal tolerance to tissue acceptance [J].
Carosella, Edgardo D. ;
Moreau, Philippe ;
Le Maoult, Joel ;
Le Discorde, Magali ;
Dausset, Jean ;
Rouas-Freiss, Nathalie .
ADVANCES IN IMMUNOLOGY, VOL 81, 2003, 81 :199-+
[9]   Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library [J].
Chames, P ;
Hufton, SE ;
Coulie, PG ;
Uchanska-Ziegler, B ;
Hoogenboom, HR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :7969-7974
[10]   HLA-G in melanoma: can the current controversies be solved? [J].
Chang, CC ;
Ferrone, S .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (05) :361-369